This study is to assess the efficacy and safety of lenalidomide in combination with
adriamycin and low dose dexamethasone in newly diagnosed patients with symptomatic multiple
myeloma as well as to collect information regarding the effect of this regimen on
angiogenesis and bone remodeling of the study population.